MEI Pharma Inc (MEIP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MEI Pharma Inc (MEIP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014326
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MEI Pharma Inc (MEI), formerly Marshall Edwards Inc is an oncology company that offers clinical development of novel therapies for cancer. The company’s drug candidates comprise pracinostat, an oral HDAC inhibitor which is intended for the treatment of acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis. Its also develops ME-344, a mitochondrial inhibitor for the treatment of HER2-negative Breast indication; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies. The company partners with other drug developers to produce Pracinostat in AML and myelodysplastic syndrome indications. MEI is headquartered in San Diego, California, the US.

MEI Pharma Inc (MEIP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
MEI Pharma Acquires PWT143 From Pathway Therapeutics 12
MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To US$76 Million 13
Marshall Edwards Completes Acquisition Of Intellectual Property Portfolio From Novogen 15
Partnerships 17
Helsinn Enters into Agreement with MEI Pharma 17
Licensing Agreements 18
MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18
Helsinn Enters into Licensing Agreement with MEI Pharma 19
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21
Marshall Edwards Enters Into Licensing Agreement With Ausio Pharma 22
Equity Offering 23
MEI Pharma Raises USD46 Million in Public Offering of Shares 23
MEI Pharma Completes Public Offering Of Shares For US$35 Million 25
MEI Pharma Completes Public Offering Of Shares For US$15 Million 26
MEI Pharma Completes Private Placement Of Units For US$27.5 Million 27
Marshall Edwards Completes Rights Offering Of Units For US$5.2 Million 29
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 30
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 32
Marshall Edwards Completes Private Placement Of Common Stock For US$1.1 Million 33
Marshall Edwards Completes First Tranche Of Public Offering Of Common Stock For US$0.13 Million 35
MEI Pharma Inc – Key Competitors 36
MEI Pharma Inc – Key Employees 37
MEI Pharma Inc – Locations And Subsidiaries 38
Head Office 38
Recent Developments 39
Financial Announcements 39
Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 39
Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 40
May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 42
Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 43
Nov 09, 2016: MEI Pharma Reports First Quarter Fiscal Year 2017 Results 45
Sep 06, 2016: MEI Pharma Reports Fiscal Year 2016 Results 47
Corporate Communications 49
Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 49
Product News 50
06/03/2016: Presage Biosciences Appoints David Johnson to Board of Directors 50
Clinical Trials 51
Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
MEI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MEI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MEI Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
MEI Pharma Acquires PWT143 From Pathway Therapeutics 12
MEI Pharma Completes Acquisition Of Rights To Pracinostat From S*BIO For Up To US$76 Million 13
Marshall Edwards Completes Acquisition Of Intellectual Property Portfolio From Novogen 15
Helsinn Enters into Agreement with MEI Pharma 17
MEI Pharma Enters into Licensing Agreement with Presage Biosciences 18
Helsinn Enters into Licensing Agreement with MEI Pharma 19
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 20
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 21
Marshall Edwards Enters Into Licensing Agreement With Ausio Pharma 22
MEI Pharma Raises USD46 Million in Public Offering of Shares 23
MEI Pharma Completes Public Offering Of Shares For US$35 Million 25
MEI Pharma Completes Public Offering Of Shares For US$15 Million 26
MEI Pharma Completes Private Placement Of Units For US$27.5 Million 27
Marshall Edwards Completes Rights Offering Of Units For US$5.2 Million 29
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 30
Marshall Edwards Completes Private Placement Of Common Stock For US$2 Million 32
Marshall Edwards Completes Private Placement Of Common Stock For US$1.1 Million 33
Marshall Edwards Completes First Tranche Of Public Offering Of Common Stock For US$0.13 Million 35
MEI Pharma Inc, Key Competitors 36
MEI Pharma Inc, Key Employees 37

★海外企業調査レポート[MEI Pharma Inc (MEIP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Prescient Therapeutics Ltd (PTX):企業の財務・戦略的SWOT分析
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a biotechnology company which develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a …
  • Iwatani Corp (8088):企業の財務・戦略的SWOT分析
    Iwatani Corp (8088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OncoMed Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    OncoMed Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's OncoMed Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • DPT Laboratories Ltd:企業の戦略的SWOT分析
    DPT Laboratories Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Gordon Food Service Inc:企業の戦略的SWOT分析
    Gordon Food Service Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • China International Marine Containers (Group) Co Ltd:企業のM&A・事業提携・投資動向
    China International Marine Containers (Group) Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China International Marine Containers (Group) Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes busines …
  • Vermillion Inc (VRML):医療機器:M&Aディール及び事業提携情報
    Summary Vermillion Inc (Vermillion) is a medical device company that discovers, develops and markets diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, a simple blood test …
  • Absher Construction Company:企業の戦略・SWOT・財務情報
    Absher Construction Company - Strategy, SWOT and Corporate Finance Report Summary Absher Construction Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cognition Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cognition Therapeutics Inc (CogRx) is a drug discovery and development company that discovers and develops small molecule therapeutics to improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platf …
  • Ingram Entertainment Inc.:企業の戦略・SWOT・財務分析
    Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report Summary Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Peako Ltd (PKO):企業の財務・戦略的SWOT分析
    Summary Peako Ltd (Peako), formerly Peak Oil & Gas Ltd, is a mineral exploration company. The company carries out the business of acquisition, exploration, and development of gold, silver and copper metals. Its projects include East Kimberley Region and Paterson Province. Peako’s East Kimberley Regi …
  • Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma …
  • French National Institute of Health and Medical Research-医療機器分野:企業M&A・提携分析
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • Medical College of Wisconsin-医療機器分野:企業M&A・提携分析
    Summary Medical College of Wisconsin (MCW) is a medical educational institution that offers biomedical education, patient care and research services. The college provides medical courses in the fields of biomedical sciences, post-doctoral education, patient and public health. It offers these courses …
  • Orsted AS (DENERG)-石油・ガス分野:企業M&A・提携分析
    Summary Orsted AS (Orsted) formerly Dong Energy A/S is an integrated energy company that procures, produces, distributes and trades energy and energy related products. It generates electricity and heat using conventional fuel and wind energy sources. The company also develops, constructs, owns and o …
  • Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報
    Summary Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended …
  • Davide Campari-Milano SpA:企業の戦略・SWOT・財務情報
    Davide Campari-Milano SpA - Strategy, SWOT and Corporate Finance Report Summary Davide Campari-Milano SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Totally Plc (TLY):企業の財務・戦略的SWOT分析
    Summary Totally plc (Totally) is a healthcare service provider that offers positive health and financial solutions. The center designs, implements and delivers coaching services to the healthcare sector, and supports individuals to better understand their healthcare options. It offers treatments and …
  • Elron Electronic Industries Ltd (ELRNF):医療機器:M&Aディール及び事業提携情報
    Summary Elron Electronic Industries Ltd (Elron), a subsidiary of IDB Holding Corp Ltd, is a provider of medical device and cyber technology solutions. The company offers development of patient care systems for stroke care, microbiology, age-related macular degeneration, orthopedics, and heart diseas …
  • Anthem, Inc.:企業の戦略・SWOT・財務情報
    Anthem, Inc. - Strategy, SWOT and Corporate Finance Report Summary Anthem, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆